Calcium Phosphate Cement as Bone Void Filler

January 13, 2022 updated by: Bioceramed

CALCIUM PHOSPHATE CEMENT AS BONE VOID FILLER - a Prospective Cohort Study in Patients Indicated for Long Bone and Extremity Surgery

This is an observational, prospective, non-randomised, post market clinical follow-up study to compile clinical data on performance and safety of the synthetic bone graft substitute and to assess that the performance and safety of the device are maintained until the reaching of its intended use in a commercial clinical setting in long bone and extremity defects.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Study Type

Observational

Enrollment (Anticipated)

40

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Lisboa, Portugal
        • Recruiting
        • Hospital Lusiadas Lisboa

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

The study population is considered as all the patients included in the study that meet the inclusion and exclusion criteria.

Description

Inclusion Criteria:

  • Patients requiring bone grafting after post-traumatic or surgically created bone defects afflicting the long bones and extremities.
  • Give written informed consent to participate in the study and be willing to comply with the protocol requirements.
  • Able to verbalize and differentiate regarding the location and intensity of pain.
  • Physical and mental availability to meet the clinical and radiographic follow-up schedule.

Exclusion Criteria:

  • Serious infection within two months before surgery.
  • Active malignancy, Cellulitis, Osteomyelitis, Osteomyelitis, Bone metastasis, Other bone metabolic diseases.
  • Primary bone tumors and contraindications in performing an X-ray or CTscan.
  • Women of childbearing potential who are, or plan to become, pregnant during the time of the study.
  • The subject is unable or not willing to complete follow-up visits and examination for the duration of the study.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Calcium Phosphate Cement (CPC)
Evaluation of CPC in long bone & extremities
Filling bone defects in current clinical practice

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Radiological healing
Time Frame: 3 months
Bone healing observable by x-ray/CT-scan. Assessment of trabecular defects: modified Neer classification. Assessment of cortical defects: modified RUST.
3 months
Radiological healing
Time Frame: 6 months
Bone healing observable by x-ray/CT-scan. Assessment of trabecular defects: modified Neer classification. Assessment of cortical defects: modified RUST.
6 months
Radiological healing
Time Frame: 9 months
Bone healing observable by x-ray/CT-scan. Assessment of trabecular defects: modified Neer classification. Assessment of cortical defects: modified RUST.
9 months
Radiological healing
Time Frame: 12 months
Bone healing observable by x-ray/CT-scan. Assessment of trabecular defects: modified Neer classification. Assessment of cortical defects: modified RUST.
12 months
Radiological healing
Time Frame: 18 months
Bone healing observable by x-ray/CT-scan. Assessment of trabecular defects: modified Neer classification. Assessment of cortical defects: modified RUST.
18 months
Radiological healing
Time Frame: 24 months
Bone healing observable by x-ray/CT-scan. Assessment of trabecular defects: modified Neer classification. Assessment of cortical defects: modified RUST.
24 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Number and description of any adverse event during the follow-up
Time Frame: 3 months
Record and description of any adverse event during the follow-up that reflects the safety of the bone graft substitute.
3 months
Number and description of any adverse event during the follow-up
Time Frame: 6 months
Record and description of any adverse event during the follow-up that reflects the safety of the bone graft substitute.
6 months
Number and description of any adverse event during the follow-up
Time Frame: 9 months
Record and description of any adverse event during the follow-up that reflects the safety of the bone graft substitute.
9 months
Number and description of any adverse event during the follow-up
Time Frame: 12 months
Record and description of any adverse event during the follow-up that reflects the safety of the bone graft substitute.
12 months
Number and description of any adverse event during the follow-up
Time Frame: 18 months
Record and description of any adverse event during the follow-up that reflects the safety of the bone graft substitute.
18 months
Number and description of any adverse event during the follow-up
Time Frame: 24 months
Record and description of any adverse event during the follow-up that reflects the safety of the bone graft substitute.
24 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ACTUAL)

January 5, 2020

Primary Completion (ANTICIPATED)

June 1, 2022

Study Completion (ANTICIPATED)

June 1, 2023

Study Registration Dates

First Submitted

November 16, 2020

First Submitted That Met QC Criteria

November 19, 2020

First Posted (ACTUAL)

November 27, 2020

Study Record Updates

Last Update Posted (ACTUAL)

January 14, 2022

Last Update Submitted That Met QC Criteria

January 13, 2022

Last Verified

January 1, 2022

More Information

Terms related to this study

Other Study ID Numbers

  • 2019.04

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Bone Defects

Clinical Trials on bone graft substitute

3
Subscribe